A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder [EXTENSION OF 700054730]

Trial Profile

A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder [EXTENSION OF 700054730]

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 01 Sep 2015 Pooled analysis results (NCT00761306, NCT00694304, NCT00707980, NCT01323478 and NCT01152996) presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Sep 2015 Pooled subgroup analysis results ((NCT00761306, NCT00694304, NCT00707980, NCT01323478 and NCT01152996)) presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top